KAHR

KAHR Announces Appointment of Jennifer Minai-Azary to its Board of Directors

Retrieved on: 
Monday, July 11, 2022
Accounting, Ernst & Young, Lymphatic system, University, Therapy, Industry, Tumor microenvironment, Company, Treasury, Immunotherapy, KAHR, Jennifer, Risk management, Patient, Board, Sustainability Accounting Standards Board, Board of directors, Pharmaceutical industry, Medicine

JERUSALEM, July 11, 2022 /PRNewswire/ -- KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, todayannouncedthe appointment of Jennifer Minai-Azary to its Board of Directors.

Key Points: 
  • JERUSALEM, July 11, 2022 /PRNewswire/ -- KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, todayannouncedthe appointment of Jennifer Minai-Azary to its Board of Directors.
  • "I am very pleased to welcome Jennifer to KAHR's Board of Directors.
  • "I'm excited to join KAHR's Board at such a meaningful time for the Company," said Jennifer Minai-Azary.
  • Jennifer Minai-Azaryis a leading financial executive, with more than 20 years ofexperience, primarily within the life sciences industry.

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

Retrieved on: 
Thursday, February 17, 2022
Myelodysplastic syndrome, Roche, Patient, Global Monitoring Plan, Cancer, LSU, Tumor necrosis factor, Human, MDS, Toxic epidermal necrolysis, CD47, Neoplasm, KAHR, Acute myeloid leukemia, Tumor microenvironment, Clinical trial, LP, Safety, Venetoclax, Therapy, University, MD, Children's Art Project at The University of Texas MD Anderson Cancer Center, Monroe Dunaway Anderson, MD Anderson Cancer Center, Partnership, Anderson, Pharmacokinetics, Lymphatic system, Research, Palestinian National Interest Committee, AML, Azacitidine, Macrophage, Pharmaceutical industry, Vaccine, Leukemia

The clinical trial is being funded by a previously announced investment from Cancer Focus Fund.

Key Points: 
  • The clinical trial is being funded by a previously announced investment from Cancer Focus Fund.
  • "This trial in challenging blood cancers complements our ongoing Phase 1/2 clinical trial in patients with advanced solid tumors.
  • DSP107 is in a Phase 1/2 clinical trial for solid tumor cancers and a Phase 1b trial for blood cancers.
  • DSP107 is being tested in a Phase 1b clinical trial in blood cancers and a Phase1/2 clinical trial in advanced solid tumors.

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers

Retrieved on: 
Thursday, September 2, 2021
Company, CD47, Cancer, Myelodysplastic syndrome, Trial of the century, Immune system, University, Pharmacokinetics, AML, Hematological Cancer Research Investment and Education Act, Food, MD Anderson Cancer Center, KAHR, MDS, LP, Lymphatic system, IND, Safety, Venetoclax, Patient, Acute myeloid leukemia, FDA, Neoplasm, Immunology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine

"The FDA clearance to commence our Phase 1b clinical trial for DSP107 in hematological cancers is a significant milestone for KAHR as we advance into the clinic with our second clinical study for our lead program with the backing and support of the Cancer Focus Fund," saidYaron Pereg, Ph.D., Chief Executive Officer of KAHR.

Key Points: 
  • "The FDA clearance to commence our Phase 1b clinical trial for DSP107 in hematological cancers is a significant milestone for KAHR as we advance into the clinic with our second clinical study for our lead program with the backing and support of the Cancer Focus Fund," saidYaron Pereg, Ph.D., Chief Executive Officer of KAHR.
  • We look forward to the topline results from the dose-escalation monotherapy part of the solid tumors study in addition to the initiation of the Phase 1b clinical trial in blood cancers, both expected in the fourth quarter of this year."
  • "Achieving FDA clearance for the commencement of the Phase 1b clinical trial showcases KAHR's ability to execute its regulatory strategy, and we look forward to the launch of the trial."
  • KAHR is developing the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer.